PTX.AXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 15:10):

Stats
本日の出来高	762 848
平均出来高	1.17M
時価総額	41.88M
EPS	$0 ( 2024-02-21 )
Last Dividend	$7.15 ( 1993-10-21 )
Next Dividend	$0 ( N/A )
P/E	-5.20
ATR14	$0.00100 (1.89%)

Prescient Therapeutics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Prescient Therapeutics 財務諸表

Annual	2023
収益:	$2.43M
総利益:	$2.43M (99.91 %)
EPS:	$-0.00960

FY	2023
収益:	$2.43M
総利益:	$2.43M (99.91 %)
EPS:	$-0.00960

FY	2022
収益:	$1.89M
総利益:	$1.89M (99.93 %)
EPS:	$-0.00790

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00680

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$5.72	1990-10-25
Last Dividend	$7.15	1993-10-21
Next Dividend	$0	N/A
Payout Date	1993-12-31
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$12.87	--
Avg. Dividend % Per Year	0.00%	--
Score	0.22	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2026-10-05)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.22

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SKC.AX	Ex Dividend Junior	2023-09-07	Annually	0.00%
CKF.AX	Ex Dividend Knight	2023-07-10	Semi-Annually	0.00%
MOT.AX	Ex Dividend Knight	2023-08-31	Monthly	0.00%
VEA.AX	Ex Dividend Junior	2023-09-05	Semi-Annually	0.00%
DTL.AX	Ex Dividend Knight	2023-09-14	Semi-Annually	0.00%
OPH.AX	No Dividend Player	2023-06-30	Annually	0.00%
AGL.AX	Ex Dividend Knight	2023-08-23	Semi-Annually	0.00%
GEM.AX	Ex Dividend Junior	2023-09-07	Annually	0.00%
QRI.AX	Ex Dividend Junior	2023-09-05	Monthly	0.00%
BFG.AX	Ex Dividend Junior	2023-08-30	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-2.49	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.313	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.318	1.500	-4.65	-6.97	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	10.26	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	9.96	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.08	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00635	[0 - 30]
freeCashFlowPerShareTTM	-0.00952	2.00	-0.00476	-0.00952	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	1.000	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-3.71	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.126	0.800	-2.50	-1.996	[0.5 - 2]
Total Score				-0.920

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.51	1.000	-0.658	0	[1 - 100]
returnOnEquityTTM	-0.318	2.50	-2.99	-6.97	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00952	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00635	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.911	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.46	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.